ERAGEM initiated its vaccine development activities in 2013.
ERAGEM was officially established by the regulation published in the Official Gazette dated May 3, 2015, issue number 29344.
The Phase 1 clinical trial of the inactivated virus vaccine developed against CCHF has been successfully completed with 52 volunteers.
The pilot facility infrastructure project required for clinical studies has been approved by the Presidency of Strategy and Budget.
The TÜBİTAK-supported CCHF vaccine project has been completed, and the developed adenovirus-based vaccine provided 100% protection in animal models.
Following the detection of SARS-CoV-2 in Turkey, vaccine development efforts against COVID-19 were initiated within ERAGEM.
Following Phase 3 clinical trials, the TURKOVAC vaccine received Emergency Use Authorization in December 2021.
Adenovirus vector-based CCHF vaccine development studies have been resumed.
